Estée Lauder
No proof required
Up to $5,000
Claims opening soon
M
Mylan
Mylan agreed to pay $264 million to settle claims it conspired to raise EpiPen prices, benefiting those who paid or reimbursed for EpiPens between 2011 and 2020.
ClosedUnited States-wideClaim status: Closed on July 25, 2022Payout: VariesNo longer claimable
About this settlement
The settlement compensates individuals and entities who paid for or reimbursed branded or generic EpiPens during the specified period, without requiring proof of purchase initially.
This settlement resolves allegations that Mylan conspired with Pfizer and others to artificially inflate the price of EpiPens, a life-saving epinephrine injector, causing consumers and payors to overpay from 2011 to 2020.
Who qualifies
- Individuals who purchased branded or generic EpiPens between August 24, 2011 and November 1, 2020.
- Entities that provided reimbursement for EpiPens during the same period.
Varies
Claim status: Closed on July 25, 2022
Silk and Great Value
Proof required
Up to $300,000
96 days left
Audible
No proof required
Compensation pending
Claims opening soon
Government of Canada
Proof required
Up to $200,000
746 days left
Meta (Facebook)
No proof required
Up to $90
Claims opening soon
Ticketmaster
No proof required
Compensation pending
Claims opening soon